Takeda Pharmaceutical
285 hedge funds and large institutions have $1.15B invested in Takeda Pharmaceutical in 2024 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 90 increasing their positions, 102 reducing their positions, and 55 closing their positions.
671% more call options, than puts
Call options by funds: $23.6M | Put options by funds: $3.06M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0.19% less ownership
Funds ownership: 2.49% → 2.3% (-0.19%)
10% less funds holding
Funds holding: 315 → 285 (-30)
12% less repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 102
47% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 55
48% less capital inflows, than outflows
Capital inflows: $83.6M | Capital outflows: $162M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$26.8M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$12.6M |
| 3 |
Cowen and Company
New York
|
+$7.02M |
| 4 |
VanEck Associates
New York
|
+$4.71M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$4.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mondrian Investment Partners
London,
United Kingdom
|
-$57.5M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$15.9M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$8.17M |
| 4 |
BlackRock
New York
|
-$7.39M |
| 5 |
Goldman Sachs
New York
|
-$6.51M |
TAK Hedge Fund Activity: Q2 2024 in Review
285 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q2 2024, worth a combined $1.15B — up 5.3% from $1.09B a quarter earlier.
Sellers outnumbered buyers: 55 funds closed out of TAK and 29 opened new positions — a net loss of 26 holders — while 102 trimmed existing stakes and 90 added.
The largest buyer was Millennium Management, adding an estimated $26.8M. The largest seller was Mondrian Investment Partners, cutting an estimated $57.5M.
- 285 institutional investors held Takeda Pharmaceutical (TAK) as of Q2 2024, down from 315 in Q1 2024.
- Funds reported $1.15B of Takeda Pharmaceutical stock for Q2 2024, up 5.3% quarter-over-quarter.
- 29 funds opened new Takeda Pharmaceutical positions in Q2 2024 and 55 closed out, a net change of -26 holders.
- The largest Takeda Pharmaceutical buyer in Q2 2024 was Millennium Management, an estimated $26.8M added.
- The largest Takeda Pharmaceutical seller in Q2 2024 was Mondrian Investment Partners, an estimated $57.5M sold.
Based on aggregated 13F filings for Q2 2024.